Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 12/2003

01-12-2003 | Original Article

Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder

Authors: Chan-Hyung Kim, Min-Seong Koo, Keun-Ah Cheon, Young-Hoon Ryu, Jong-Doo Lee, Hong-Shick Lee

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2003

Login to get access

Abstract

It has been suggested that dopamine, as well as serotonin, is associated with the pathophysiology of obsessive-compulsive disorder (OCD). Thus, many studies have been performed on brain regions associated with dopamine in patients with OCD. In the present study, we investigated the DAT density of the basal ganglia using iodine-123 labelled N-(3-iodopropen-2-yl)-2β-carbomethoxy-3β-(4-chlorophenyl) tropane ([123I]IPT) single-photon emission tomography (SPET) and evaluated the activity of the presynaptic dopamine function in patients with OCD. Fifteen patients with OCD and 19 normal control adults were included in the study. We performed brain SPET 2 h after the intravenous administration of [123I]IPT and carried out both quantitative and qualitative analyses using the obtained SPET data, which were reconstructed for the assessment of the specific/non-specific dopamine transporter (DAT) binding ratio in the basal ganglia. We then investigated the correlation between the severity scores of OCD symptoms assessed with the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) and the specific/non-specific DAT binding ratio of the basal ganglia. Compared with normal control adults, patients with OCD showed a significantly increased specific/non-specific DAT binding ratio in the right basal ganglia and a tendency towards an increased specific/non-specific DAT binding ratio in the left basal ganglia. No significant correlation was found between the total scores on the Y-BOCS and the specific/non-specific DAT binding ratio of the basal ganglia. These findings suggest that the dopaminergic neurotransmitter system of the basal ganglia in patients with OCD could be involved in the pathophysiology of OCD.
Literature
1.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington DC: American Psychiatric Press, 1994. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington DC: American Psychiatric Press, 1994.
2.
go back to reference Stein DJ. Neurobiology of the obsessive-compulsive spectrum disorders. Biol Psychiatry 2000; 47:296–304.CrossRefPubMed Stein DJ. Neurobiology of the obsessive-compulsive spectrum disorders. Biol Psychiatry 2000; 47:296–304.CrossRefPubMed
3.
go back to reference Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987; 22:667–687.PubMed Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987; 22:667–687.PubMed
4.
go back to reference Goodman WK, McDougle CJ, Price LH, Riddle MA, Pauls DL, Leckman JF. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry 1990; 51:S36–S43. Goodman WK, McDougle CJ, Price LH, Riddle MA, Pauls DL, Leckman JF. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry 1990; 51:S36–S43.
6.
go back to reference Brambilla F, Bellodi L, Perna G, Arancio C, Bertani A. Dopamine function in obsessive compulsive disorder: growth hormone response to apomorphine stilmulation. Biol Psychiatry 1997; 15:889–897.CrossRef Brambilla F, Bellodi L, Perna G, Arancio C, Bertani A. Dopamine function in obsessive compulsive disorder: growth hormone response to apomorphine stilmulation. Biol Psychiatry 1997; 15:889–897.CrossRef
7.
go back to reference Swedo SE, Rapoport JL, Leonard H, Lenane M, Cheslow D. Obsessive-compulsive disorder in children and adolescents. Clinical phenomenology of 70 consecutive cases. Arch Gen Psychiatry 1989; 46:335–341.PubMed Swedo SE, Rapoport JL, Leonard H, Lenane M, Cheslow D. Obsessive-compulsive disorder in children and adolescents. Clinical phenomenology of 70 consecutive cases. Arch Gen Psychiatry 1989; 46:335–341.PubMed
8.
go back to reference Swedo SE, Leonard HL, Schapiro MB, et al. Sydenham's chorea: physical and psychological symptoms of St. Vitus dance. Pediatrics 1993; 91:706–713.PubMed Swedo SE, Leonard HL, Schapiro MB, et al. Sydenham's chorea: physical and psychological symptoms of St. Vitus dance. Pediatrics 1993; 91:706–713.PubMed
9.
go back to reference Leonard HL, Lenane MC, Swedo SE, Rettew DC, Gershon ES, Rapoport JL. Tics and Tourette's disorder: a 2- to 7-year follow-up of 54 obsessive-compulsive children. Am J Psychiatry 1992; 149:1244–1251.PubMed Leonard HL, Lenane MC, Swedo SE, Rettew DC, Gershon ES, Rapoport JL. Tics and Tourette's disorder: a 2- to 7-year follow-up of 54 obsessive-compulsive children. Am J Psychiatry 1992; 149:1244–1251.PubMed
10.
go back to reference Agid O, Lerer B. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology. J Clin Psychiatry 1999; 60:55–60.PubMed Agid O, Lerer B. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology. J Clin Psychiatry 1999; 60:55–60.PubMed
11.
go back to reference McDougle CJ, Goodman WK, Price LH, et al. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990; 147:652–654.PubMed McDougle CJ, Goodman WK, Price LH, et al. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990; 147:652–654.PubMed
12.
go back to reference McDougle CJ, Goodman WK, Leckman JF. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994; 51:302–308.PubMed McDougle CJ, Goodman WK, Leckman JF. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994; 51:302–308.PubMed
13.
go back to reference Rauch SL, Whalen PJ, Curran T, et al. Probing striato-thalamic function in obsessive-compulsive disorder and Tourette syndrome using neuroimaging methods. Adv Neurol 2001; 85:207–224.PubMed Rauch SL, Whalen PJ, Curran T, et al. Probing striato-thalamic function in obsessive-compulsive disorder and Tourette syndrome using neuroimaging methods. Adv Neurol 2001; 85:207–224.PubMed
14.
go back to reference Saxena S, Brody AL, Schwartz JM, Baxter LR. Neuroimaging and fronto-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry 1998; 35:S26–S37. Saxena S, Brody AL, Schwartz JM, Baxter LR. Neuroimaging and fronto-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry 1998; 35:S26–S37.
15.
go back to reference Fitzgerald KD, MacMaster FP, Paulson LD, Rosenberg DR. Neurobiology of childhood obsessive-compulsive disorder. Child Adolesc Psychiatr Clin North Am 1999; 8:533–575. Fitzgerald KD, MacMaster FP, Paulson LD, Rosenberg DR. Neurobiology of childhood obsessive-compulsive disorder. Child Adolesc Psychiatr Clin North Am 1999; 8:533–575.
16.
go back to reference Rosenberg DR, Benazon NR, Gilbert A, Sullivan A, Moore GJ. Thalamic volume in pediatric obsessive-compulsive disorder patients before and after cognitive behavioral therapy. Biol Psychiatry 2000; 48:294–300.CrossRefPubMed Rosenberg DR, Benazon NR, Gilbert A, Sullivan A, Moore GJ. Thalamic volume in pediatric obsessive-compulsive disorder patients before and after cognitive behavioral therapy. Biol Psychiatry 2000; 48:294–300.CrossRefPubMed
17.
go back to reference Breiter HC, Rauch SL, Kwong KK, et al. Functional magnetic resonance imaging of symptom provocation in obsessive compulsive disorder. Arch Gen Psychiatry 1996; 53:595–606.PubMed Breiter HC, Rauch SL, Kwong KK, et al. Functional magnetic resonance imaging of symptom provocation in obsessive compulsive disorder. Arch Gen Psychiatry 1996; 53:595–606.PubMed
18.
go back to reference Insel TR. Toward a neuroanatomy of obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49:739–744.PubMed Insel TR. Toward a neuroanatomy of obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49:739–744.PubMed
19.
go back to reference Rauch SL, Jenike MA, Alpert NM, et al. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 1994; 51:62–70.PubMed Rauch SL, Jenike MA, Alpert NM, et al. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 1994; 51:62–70.PubMed
20.
go back to reference Rauch SL, Savage CR. Neuroimaging and neuropsychology of the striatum. Psychiatr Clin North Am 1997; 20:741–768.PubMed Rauch SL, Savage CR. Neuroimaging and neuropsychology of the striatum. Psychiatr Clin North Am 1997; 20:741–768.PubMed
21.
go back to reference Saxena S, Brody AL, Ho ML, et al. Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Arch Gen Psychiatry 2002; 59:250–261.CrossRefPubMed Saxena S, Brody AL, Ho ML, et al. Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Arch Gen Psychiatry 2002; 59:250–261.CrossRefPubMed
22.
go back to reference Schwartz JM, Stoessel PW, Baxter LR Jr, Martin KM, Phelps ME. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive compulsive disorder. Arch Gen Psychiatry 1996; 53:109–113.PubMed Schwartz JM, Stoessel PW, Baxter LR Jr, Martin KM, Phelps ME. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive compulsive disorder. Arch Gen Psychiatry 1996; 53:109–113.PubMed
23.
go back to reference Saxena S, Brody AL, Maidment KM, et al. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 1999; 21:683–693. Saxena S, Brody AL, Maidment KM, et al. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 1999; 21:683–693.
24.
go back to reference Campbell KM, de Lecea L, Severynse DM, et al. OCD-like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1 neurons. J Neurosci 1999; 15:5044–5053. Campbell KM, de Lecea L, Severynse DM, et al. OCD-like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1 neurons. J Neurosci 1999; 15:5044–5053.
25.
go back to reference Bao SY, Wu JC, Lo WF, Fang P, Liu ZL, Tang J. Imaging of dopamine transporters with technetium-99m TRODAT-1 and single photon emission computed tomography. J Neuroimaging 2000; 10:200–203.PubMed Bao SY, Wu JC, Lo WF, Fang P, Liu ZL, Tang J. Imaging of dopamine transporters with technetium-99m TRODAT-1 and single photon emission computed tomography. J Neuroimaging 2000; 10:200–203.PubMed
26.
go back to reference Dresel D, Krause J, Krause KH, et al. Attention deficit hyperactivity disorder: binding of 99m-Tc-TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med 2000; 27:1518–1524.CrossRefPubMed Dresel D, Krause J, Krause KH, et al. Attention deficit hyperactivity disorder: binding of 99m-Tc-TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med 2000; 27:1518–1524.CrossRefPubMed
27.
go back to reference Huang WS, Lin JS, Lin JC, Wey SP, Ting G, Liu RS. Evaluation of early stage Parkinson's disease with99mTc-TRODAT-1 imaging. J Nucl Med 2001; 42:1303–1308.PubMed Huang WS, Lin JS, Lin JC, Wey SP, Ting G, Liu RS. Evaluation of early stage Parkinson's disease with99mTc-TRODAT-1 imaging. J Nucl Med 2001; 42:1303–1308.PubMed
28.
go back to reference Mozley PD, Schneider JS, Acton PD, et al. Binding of99mTc-TRODAT-1 to dopamine transporter in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 2000; 41:584–589.PubMed Mozley PD, Schneider JS, Acton PD, et al. Binding of99mTc-TRODAT-1 to dopamine transporter in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 2000; 41:584–589.PubMed
29.
go back to reference Madras BK, Jones AG, Mahmood A, et al. Technepine: a high affinity technetium-99m probe to label the dopamine transporter in brain by SPECT imaging. Synapse 1996; 22:239–246.CrossRefPubMed Madras BK, Jones AG, Mahmood A, et al. Technepine: a high affinity technetium-99m probe to label the dopamine transporter in brain by SPECT imaging. Synapse 1996; 22:239–246.CrossRefPubMed
30.
go back to reference Church WH, Justice JB Jr, Byrd LD. Extracellular dopamine in rat striatum following uptake inhibition by cocaine, nomifensine and benztropine. Eur J Pharmacol 1987; 139:345–348.PubMed Church WH, Justice JB Jr, Byrd LD. Extracellular dopamine in rat striatum following uptake inhibition by cocaine, nomifensine and benztropine. Eur J Pharmacol 1987; 139:345–348.PubMed
31.
go back to reference Fowler JS, Volkow ND, Wolf AP, et al. Mapping cocaine-binding sites in human and baboon brain in vivo. Synapse 1989; 4:371–377.PubMed Fowler JS, Volkow ND, Wolf AP, et al. Mapping cocaine-binding sites in human and baboon brain in vivo. Synapse 1989; 4:371–377.PubMed
32.
go back to reference Hurd YL, Ungerstedt U. Cocaine: an in vivo microdialysis evaluation of its acute action on dopamine transmission in rat striatum. Synapse 1989; 3:48–54.PubMed Hurd YL, Ungerstedt U. Cocaine: an in vivo microdialysis evaluation of its acute action on dopamine transmission in rat striatum. Synapse 1989; 3:48–54.PubMed
33.
go back to reference Billings JJ, Guo YZ, Kung MP, Kung HF. Localization of IBF as a D2 dopamine receptor parameters in nonhuman primates. Eur J Nucl Med Mol Imaging 1993; 20:1146–1153. Billings JJ, Guo YZ, Kung MP, Kung HF. Localization of IBF as a D2 dopamine receptor parameters in nonhuman primates. Eur J Nucl Med Mol Imaging 1993; 20:1146–1153.
34.
go back to reference Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999; 26:171–182.CrossRefPubMed Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999; 26:171–182.CrossRefPubMed
35.
go back to reference Laurelle M, van Dyck C, Abi-Dargham A, et al. Compartmental modelling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects. J Nucl Med 1994; 35:743–754. Laurelle M, van Dyck C, Abi-Dargham A, et al. Compartmental modelling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects. J Nucl Med 1994; 35:743–754.
36.
go back to reference Hahn OS, Ahn JH, Song SH, et al. Development of Korean Version of Structured Clinical Interview Schedule for DSM-IV Axis I Disorder: Interrater Reliability. J Korean Neuropsychiatric Assoc 2000; 39:362–372. Hahn OS, Ahn JH, Song SH, et al. Development of Korean Version of Structured Clinical Interview Schedule for DSM-IV Axis I Disorder: Interrater Reliability. J Korean Neuropsychiatric Assoc 2000; 39:362–372.
37.
go back to reference Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale: I. development, use, and reliability. Arch Gen Psychiatry 1989; 46:1006–1011.PubMed Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale: I. development, use, and reliability. Arch Gen Psychiatry 1989; 46:1006–1011.PubMed
38.
go back to reference Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: US Department of Health, Education and Welfare, 1976. Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: US Department of Health, Education and Welfare, 1976.
39.
go back to reference Kim HJ, Im JH, Yang SO, et al. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects. J Nucl Med 1997; 38:1703–1711.PubMed Kim HJ, Im JH, Yang SO, et al. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects. J Nucl Med 1997; 38:1703–1711.PubMed
40.
go back to reference Chang LT. A method for attenuation correction in ratio nuclide computed tomography. IEEE Trans Nucl Sci 1978; 25:638–643. Chang LT. A method for attenuation correction in ratio nuclide computed tomography. IEEE Trans Nucl Sci 1978; 25:638–643.
41.
go back to reference Benkelfat C, Nordahl TE, Semple WE, King C, Murphey DL, Cohen RM. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Arch Gen Psychiatry 1990; 47: 840–848.PubMed Benkelfat C, Nordahl TE, Semple WE, King C, Murphey DL, Cohen RM. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Arch Gen Psychiatry 1990; 47: 840–848.PubMed
42.
go back to reference Hoehn-Saric R, Schlaepfer TE, Greenberg BD, McLeod DR, Pearlson GD, Wong SH. Cerebral blood flow in obsessive-compulsive patients with major depression: effect of treatment with sertraline or desipramine on treatment responders and non-responders. Psychiatry Res 2001; 30:89–100. Hoehn-Saric R, Schlaepfer TE, Greenberg BD, McLeod DR, Pearlson GD, Wong SH. Cerebral blood flow in obsessive-compulsive patients with major depression: effect of treatment with sertraline or desipramine on treatment responders and non-responders. Psychiatry Res 2001; 30:89–100.
43.
go back to reference Bannon MJ, Granneman JG, Kapatos G. The dopamine transporter. Potential involvement in neuropsychiatric disorder. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation progress. New York: Raven; 1995:179–188. Bannon MJ, Granneman JG, Kapatos G. The dopamine transporter. Potential involvement in neuropsychiatric disorder. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation progress. New York: Raven; 1995:179–188.
44.
go back to reference Ciliax BJ, Heilman C, Demchyshyn LL, et al. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 1994; 15:1714–1723. Ciliax BJ, Heilman C, Demchyshyn LL, et al. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 1994; 15:1714–1723.
Metadata
Title
Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder
Authors
Chan-Hyung Kim
Min-Seong Koo
Keun-Ah Cheon
Young-Hoon Ryu
Jong-Doo Lee
Hong-Shick Lee
Publication date
01-12-2003
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2003
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-003-1245-7

Other articles of this Issue 12/2003

European Journal of Nuclear Medicine and Molecular Imaging 12/2003 Go to the issue

News & Views

December 2003